专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2014132035A Influenza vaccination 审中-公开
标题翻译：流感疫苗
公开(公告)号：JP2014132035A
公开(公告)日：2014-07-17
申请号：JP2014081555
申请日：2014-04-11
申请人： Novartis Vaccines & Diagnostic Inc , ノバルティスヴァクシンズアンドダイアグノスティクス, インコーポレイテッド
发明人： O'HAGAN DEREK
IPC分类号： A61K39/145 , A61P31/16
CPC分类号： C07K14/005 , A61K9/0021 , A61K39/12 , A61K39/145 , A61K2039/54 , A61K2039/545 , A61K2039/55 , A61K2039/55505 , A61K2039/70 , A61M37/0015 , A61M2037/0046 , A61M2037/0061 , C12N7/00 , C12N2760/16034 , C12N2760/16134 , C12N2760/16234
摘要： PROBLEM TO BE SOLVED: To provide an influenza virus vaccine, particularly a pediatric vaccine for the delivery to Langerhans cells.SOLUTION: The invention is based on the idea of using alternative routes of delivery for influenza vaccines except an intramuscular injection, more specifically routes that do not require as large a dose of antigen. Delivery of influenza antigen to the Langerhans cells is the route of choice according to the invention. This route has been found to be particularly useful for vaccinating patients who are naive to influenza virus (i.e. have not previously mounted an immune response to an influenza virus). This means that it is advantageous for immunizing young children.
摘要翻译：要解决的问题：提供流感病毒疫苗，特别是用于递送到朗格汉斯细胞的儿科疫苗。解决方案：本发明基于除了肌肉内注射之外使用流感疫苗的替代递送途径的思想，更具体地说，不需要大量的抗原。向朗格汉斯细胞递送流感抗原是根据本发明的选择途径。已经发现，这种途径对于接种流感病毒天真的患者（即先前尚未对流感病毒免疫应答）特别有用。这意味着有利于免疫幼儿。

2. 发明专利

JP2008266341A Alpha virus vector for respiratory pathogen vaccine 审中-公开
标题翻译：呼吸道病毒疫苗的ALPHA病毒载体
公开(公告)号：JP2008266341A
公开(公告)日：2008-11-06
申请号：JP2008125258
申请日：2008-05-12
申请人： Novartis Vaccines & Diagnostic Inc , ノバルティスヴァクシンズアンドダイアグノスティクス, インコーポレイテッド
发明人： PERRI SILVIA , POLO JOHN , UEMATSU YASUSHI , GREER CATHERINE
IPC分类号： A61K35/76 , A61K39/00 , A61K39/02 , A61K39/04 , A61K39/05 , A61K39/09 , A61K39/104 , A61K39/12 , A61K39/145 , A61K39/155 , A61K39/215 , A61P31/04 , A61P31/12 , C12N7/00 , C12N15/09
CPC分类号： A61K39/12 , A61K39/145 , A61K39/155 , A61K2039/5252 , A61K2039/5256 , A61K2039/53 , A61K2039/543 , A61K2039/545 , A61K2039/55544 , A61K2039/55566 , A61K2039/70 , C12N15/86 , C12N2760/16122 , C12N2760/16134 , C12N2760/18322 , C12N2760/18334 , C12N2760/18522 , C12N2760/18534 , C12N2760/18622 , C12N2760/18634 , C12N2770/20022 , C12N2770/20034 , C12N2770/36143 , C12N2830/20 , C12N2830/60 , C12N2840/20 , C12N2840/203
摘要： PROBLEM TO BE SOLVED: To provide a composition and a method for stimulating an immune response to respiratory pathogen. SOLUTION: The composition is an immunogenic composition and contains (a) a first alpha virus replicon vector/vector construct/replicon particle ((i) a first heterologous nucleic acid encoding at least one immunogenic protein derived from respiratory pathogen, (ii) a second heterologous nucleic acid encoding at least one immunogenic protein derived from respiratory pathogen and when both the first and the second nucleic acids encode an immunogenic protein derived from the same parainfluenza virus (PIV), the same RS virus (RSV) or the same SARS virus, the composition further includes a second alpha virus replicon vector/vector construct/replicon particle) and (b) a pharmaceutically acceptable carrier, a diluent and an excipient. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：要解决的问题：提供用于刺激对呼吸道病原体的免疫应答的组合物和方法。解决方案：组合物是免疫原性组合物，并且包含（a）第一个α病毒复制子载体/载体构建体/复制子颗粒（（i）编码至少一种来自呼吸道病原体的免疫原性蛋白质的第一异源核酸，）编码来自呼吸道病原体的至少一种免疫原性蛋白质的第二异源核酸，并且当第一和第二核酸两者都编码来源于相同副流感病毒（PIV）的免疫原性蛋白质，相同的RS病毒（RSV）或相同的 SARS病毒，组合物还包括第二个α病毒复制子载体/载体构建体/复制子颗粒）和（b）药学上可接受的载体，稀释剂和赋形剂。版权所有（C）2009，JPO＆INPIT

3. 发明专利

JP2012111782A Antigen from uropathogenic escherichia coli 审中-公开
标题翻译：来自UROPATHOGENIC ESCHERICHIA COLI的抗原
公开(公告)号：JP2012111782A
公开(公告)日：2012-06-14
申请号：JP2012057239
申请日：2012-03-14
申请人： Novartis Vaccines & Diagnostic Inc , ノバルティスヴァクシンズアンドダイアグノスティクス, インコーポレイテッド
发明人： PIZZA MARIAGRAZIA , SERINO LAURA , BERLANDA SCORZA FRANCESCO , GOMES MORIEL DANILO , FONTANA MARIA RITA
IPC分类号： C07K14/245 , A61K9/127 , A61K39/108 , A61K39/39 , A61P31/04 , C12N15/09
CPC分类号： C07K14/245 , A61K38/00
摘要： PROBLEM TO BE SOLVED: To provide antigens for use in immunisation against pathogenic E. coli strains, particularly ExPEC strains, and more particularly UPEC strains.SOLUTION: The inventors have identified various genes that can be included in immunogenic compositions specific for pathogenic E. coli strains. The genes are from uropathogenic strains (UPEC) but are absent from non-pathogenic strains, and their encoded proteins have cellular locations which render them accessible to the immune system. The present invention also relates to methods for raising an immune response in a patient, comprising the step of administering to the patient a pharmaceutical composition or immunogenic composition. In a particular embodiment, the immune response is protective against ExPEC infection.
摘要翻译：待解决的问题：提供用于免疫病原性大肠杆菌菌株，特别是ExPEC菌株，更特别是UPEC菌株的抗原。解决方案：本发明人已经鉴定出可以包含在致病性大肠杆菌菌株特异性的免疫原性组合物中的各种基因。这些基因来自疱疹病原菌株（UPEC），但不存在于非致病菌株中，并且其编码的蛋白质具有使其免疫系统可接近的细胞位置。本发明还涉及在患者体内提高免疫应答的方法，包括向患者施用药物组合物或免疫原性组合物的步骤。在一个具体实施方案中，免疫应答是防止ExPEC感染的。版权所有（C）2012，JPO＆INPIT

4. 发明专利

JP2012080899A Prion-specific peptide reagents 审中-公开
标题翻译：特异性肽试剂
公开(公告)号：JP2012080899A
公开(公告)日：2012-04-26
申请号：JP2011289829
申请日：2011-12-28
申请人： Novartis Vaccines & Diagnostic Inc , ノバルティスヴァクシンズアンドダイアグノスティクス, インコーポレイテッド
发明人： MICHELITSCH MELISSA , HU CELINE YUAN-HWEI , CONNOLLY MICHAEL D , ZUCKERMANN RONALD
IPC分类号： C12N15/09 , A23L5/20 , A23L33/00 , A61K35/14 , A61K38/00 , C07K16/18 , G01N33/53 , G01N33/543
CPC分类号： G01N33/6896 , A61K38/00 , C07K14/47 , G01N2800/2828
摘要： PROBLEM TO BE SOLVED: To provide peptide reagents that interacts preferentially with the PrPform of a prion protein.SOLUTION: Methods of using the reagents or antibodies to the reagents for detection, diagnosis, purification, therapy and prophylaxis for prions and prion-associated diseases are also described. The peptide reagents can be used in a wide range of applications, including as tools to isolate pathogenic prions or to detect the presence of pathogenic prions in a sample, as components of a therapeutic or prophylactic composition and/or to generate prion-specific antibodies. For example, peptide reagents that interact preferentially with PrPas compared to PrPare useful for direct detection of pathogenic forms in samples obtained from living subjects, for example, for diagnosis of a disease or for screening donated blood samples or screening organs for organ donation.
摘要翻译：要解决的问题：提供与PrP蛋白的PrP Sc 形式相互作用的肽试剂。解决方案：还描述了使用试剂或抗体用于检测，诊断，纯化，治疗和预防朊病毒和朊病毒相关疾病的方法。肽试剂可用于广泛的应用，包括作为分离致病性朊病毒的工具或检测样品中病原性朊病毒的存在，作为治疗或预防组合物的组分和/或产生朊病毒特异性抗体。例如，与PrP C 相比较，与PrP Sc 优先相互作用的肽试剂可用于直接检测样品中的病原体从活体中获得，例如用于诊断疾病或筛选捐献的血液样品或筛选器官的器官捐赠。版权所有（C）2012，JPO＆INPIT

5. 发明专利

JP2009102448A Semisynthetic desmethyl-vancomycin-based glycopeptides with antibiotic activity 审中-公开
标题翻译：具有抗生素活性的基于二硫代吗啉 - 基于血管内皮素的糖蛋白
公开(公告)号：JP2009102448A
公开(公告)日：2009-05-14
申请号：JP2009035926
申请日：2009-02-18
申请人： North China Pharmaceutical Group Corp , Novartis Vaccines & Diagnostic Inc , ノースチャイナファーマシューティカルグループコーポレイション , ノバルティスヴァクシンズアンドダイアグノスティクス, インコーポレイテッド
发明人： CHU DANIEL , NI ZHI-JIE , WANG JOHN JIAN-XIN , LEI YAOHUI , BAI YU
IPC分类号： C07K7/06 , A61K38/00 , A61P31/04
CPC分类号： C07K9/008 , A61K38/00
摘要： PROBLEM TO BE SOLVED: To identify new derivative compounds having improved effectiveness or unpredictable selectivity for targeted microorganisms. SOLUTION: Semisynthetic glycopeptides that have antibacterial activity are based on modifications of the desmethyl-vancomycin scaffold, in particular, acylation of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups; and/or conversion of the acid moiety on the macrocyclic ring of this scaffolds to certain substituted amides. In addition, compounds include desmethyl-vancomycin scaffolds (on which the acid moiety on the macrocyclic ring is converted to certain substituted amides and the amino substituent on the amino-substituted sugar moiety is alkylated with certain alkyl groups). COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：要解决的问题：鉴定具有改进的有效性或不可预测的靶向微生物选择性的新衍生化合物。具有抗菌活性的半合成糖肽基于脱甲基万古霉素支架的修饰，特别是在该支架上具有某些酰基的氨基取代的糖部分上的氨基取代基的酰化; 和/或将该支架的大环上的酸部分转化为某些取代的酰胺。此外，化合物包括脱甲基万古霉素支架（大环上的酸部分转化为某些取代的酰胺，氨基取代的糖部分上的氨基取代基被某些烷基烷基化）。版权所有（C）2009，JPO＆INPIT

6. 发明专利

JP2013252140A NEISSERIA MENINGITIDIS ANTIGEN AND COMPOSITION 审中-公开
公开(公告)号：JP2013252140A
公开(公告)日：2013-12-19
申请号：JP2013157835
申请日：2013-07-30
申请人： NOVARTIS VACCINES & DIAGNOSTIC , CRAIG J VENTER INST INC
发明人： FRASER CLAIRE , GALEOTTI CESIRA , GRANDI GUIDO , HICKEY ERIN , MASIGNANI VEGA , MORA MARIROSA , PETERSEN JEREMY , PIZZA MARIAGRATIA , RAPPUOLI RINO , RATTI GIULIO , SCALATO ENZO , SCARSELLI MARIA , TETTELIN HERVE , VENTER J CRAIG
IPC分类号： C12N15/09 , G01N33/50 , A61K38/00 , A61K39/00 , A61K39/095 , A61P31/04 , C07K14/22 , C07K16/12 , C12N15/31 , C12P21/08 , C12Q1/68 , C12R1/36
摘要： PROBLEM TO BE SOLVED: To provide Neisserial DNA sequences which encode proteins that are antigenic or immunogenic.SOLUTION: The invention provides proteins from Neisseria meningitidis, including amino acid sequences and corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics. This invention provides Neisseria meningitidis menB nucleotide sequences, amino acid sequences encoded therein. With these disclosed sequences, nucleic acid probe assays and expression cassettes and expression vectors can be produced. The expression vectors can be transformed into host cells to produce proteins.

7. 发明专利

JP2012001565A Influenza vaccination 审中-公开
标题翻译：流感疫苗
公开(公告)号：JP2012001565A
公开(公告)日：2012-01-05
申请号：JP2011219630
申请日：2011-10-03
申请人： Novartis Vaccines & Diagnostic Inc , ノバルティスヴァクシンズアンドダイアグノスティクス, インコーポレイテッド
发明人： O'HAGAN DEREK
IPC分类号： A61K39/145 , A61K39/155 , A61P31/16
CPC分类号： C07K14/005 , A61K9/0021 , A61K39/12 , A61K39/145 , A61K2039/54 , A61K2039/545 , A61K2039/55 , A61K2039/55505 , A61K2039/70 , A61M37/0015 , A61M2037/0046 , A61M2037/0061 , C12N7/00 , C12N2760/16034 , C12N2760/16134 , C12N2760/16234
摘要： PROBLEM TO BE SOLVED: To provide an influenza virus vaccine, in particular a pediatric vaccine to deliver to Langerhans cells.SOLUTION: The invention is based on the idea of using alternative routes of delivery for influenza vaccines other than intramuscular injection, more specifically routes that do not require as large a dose of antigen. Delivery of influenza antigen to the Langerhans cells is the route of choice. The route has been found to be particularly useful for vaccinating patients who are naive to influenza virus (i.e. have not previously mounted an immune response to an influenza virus). This means that it is advantageous for immunising young children.
摘要翻译：要解决的问题：提供流感病毒疫苗，特别是提供给朗格汉斯细胞的儿科疫苗。解决方案：本发明基于使用除肌肉内注射之外的流感疫苗的替代递送途径的想法，更具体地说，不需要大量抗原的途径。向朗格汉斯细胞递送流感抗原是选择的途径。已经发现该途径对于接种流感病毒幼稚的患者（即先前尚未对流感病毒免疫应答）特别有用。这意味着有利于免疫幼儿。版权所有（C）2012，JPO＆INPIT

8. 发明专利

JP2012184264A Compound for immunological enhancement 审中-公开
标题翻译：化合物用于免疫增强
公开(公告)号：JP2012184264A
公开(公告)日：2012-09-27
申请号：JP2012148640
申请日：2012-07-02
申请人： Novartis Vaccines & Diagnostic Inc , ノバルティスヴァクシンズアンドダイアグノスティクス, インコーポレイテッド
发明人： VALIANTE NICHOLAS , XU FENG , SILVER JOEL B
IPC分类号： A61K31/517 , A61K31/5377 , A61K45/00 , A61P1/04 , A61P11/06 , A61P25/00 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/04 , A61P37/08 , A61P43/00 , C07D239/94 , C07D401/12 , C07D405/04
CPC分类号： A61K31/505 , A61K31/52 , A61K31/7068 , A61K31/708 , A61K45/06
摘要： PROBLEM TO BE SOLVED: To provide a compound capable of stimulating or adjusting the immune response in a subject.SOLUTION: To provide a method for stimulating immunological response and a method for treating a responsive patient with 3,4-di (1H-indol-3-yl)1H-pyrrole-2,5-dione, staurosporin analog, derivatized pyridazine, chromene-4-one, indolinone, quinazoline, nucleoside analog, and other low molecules. In one embodiment, this patent provides a new method for administration of an immnogenic composition and vaccine on the basis of administration of the 3,4-di (1H-indol-3-yl)-1H-pyrrole-2,5-dione in combination with an antigen or some other factor.
摘要翻译：待解决的问题：提供能够刺激或调节受试者的免疫应答的化合物。解决方案：提供一种刺激免疫应答的方法和一种用3,4-二（1H-吲哚-3-基）-1H-吡咯-2,5-二酮，星形孢菌素类似物治疗患者的方法，衍生化哒嗪，色烯-4-酮，二氢吲哚酮，喹唑啉，核苷类似物等低分子。在一个实施方案中，该专利提供了一种基于将3,4-二（1H-吲哚-3-基）-1H-吡咯-2,5-二酮的给药施用于非致命组合物和疫苗的新方法与抗原或一些其他因子的组合。版权所有（C）2012，JPO＆INPIT

9. 发明专利

JP2012105686A Modified small interfering rna molecule and method of use 审中-公开
标题翻译：改良的小干扰RNA分子及其使用方法
公开(公告)号：JP2012105686A
公开(公告)日：2012-06-07
申请号：JP2012054494
申请日：2012-03-12
申请人： Novartis Vaccines & Diagnostic Inc , ノバルティスヴァクシンズアンドダイアグノスティクス, インコーポレイテッド
发明人： HUANG CHIYUAN , HOUGHTON MICHAEL
IPC分类号： C12N15/113 , A61K31/7105 , A61K31/713 , A61K45/00 , A61K48/00 , A61P31/12 , A61P31/14 , A61P31/20 , A61P43/00 , C07H21/02
CPC分类号： C12N15/1131 , A61K38/00 , C12N2310/14 , C12N2310/322 , C12N2310/334 , C12N2310/335 , C12N2310/3515
摘要： PROBLEM TO BE SOLVED: To provide a method for inactivating a hepatitis virus by inhibiting the viral replication in an infected cell using 2'-fluorine dsRNA or siRNA, relating to the field of nucleic acid detection and to the phenomenon of RNA silencing, or RNA interference (RNAi).SOLUTION: The method for inactivating the virus that causes hepatitis in a patient includes (a) s step of administering to the patient a modified double-stranded RNA (dsRNA) or modified short-chain interfering RNA (siRNA) in an effective amount to inactivate the virus and (b) a step of administering to the patient a cholesterol-lowering drug.
摘要翻译：待解决的问题：提供一种通过使用2'-氟dsRNA或siRNA抑制感染细胞中的病毒复制来灭活肝炎病毒的方法，涉及核酸检测领域和RNA沉默现象，或RNA干扰（RNAi）。解决方案：用于灭活患者肝炎的病毒的方法包括（a）向患者施用经修饰的双链RNA（dsRNA）或经修饰的短链干扰RNA（siRNA）的有效方法使病毒灭活，和（b）向患者施用降胆固醇药物的步骤。版权所有（C）2012，JPO＆INPIT

10. 发明专利

JP2009102446A Semisynthetic glycopeptides with antibiotic activity 审中-公开
标题翻译：具有抗生素活性的半胱氨酸蛋白酶
公开(公告)号：JP2009102446A
公开(公告)日：2009-05-14
申请号：JP2009035666
申请日：2009-02-18
申请人： Novartis Vaccines & Diagnostic Inc , ノバルティスヴァクシンズアンドダイアグノスティクス, インコーポレイテッド
发明人： CHU DANIEL , PREOBRAZHENSKAYA MARIA , PRINTSEVSKAYA SVETLANA , OLSUFYEVA EUGENIA
IPC分类号： C07K7/54 , A61K38/00 , A61P31/04
CPC分类号： A61K38/14 , C07K9/008
摘要： PROBLEM TO BE SOLVED: To identify new derivative compounds having improved effectiveness and unpredictable selectivity for targeted microorganisms. SOLUTION: Semisynthetic glycopeptides having antibacterial activity are produced based on modifications of eremomycin, A82846B, vancomycin, teicoplanin, or A-40,926 scaffolds, acylation of the sugar moieties on these scaffolds with certain acyl groups (in particular, amino acids and their derivatives); and/or conversion of an acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides; or having a combination of an alkylation modification of the amino substituent on the amino-substituted sugar moiety on these scaffolds with certain alkyl groups or acylation modification of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain alkyl groups (including β-amino acids or their derivatives), and conversion of the acid moiety on the macrocyclic ring of this scaffolds to certain substituted amides. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：要解决的问题：鉴定具有改善的有效性和不可预测的靶向微生物选择性的新衍生化合物。解决方案：具有抗菌活性的半合成糖肽基于依依霉素，A82846B，万古霉素，替考拉宁或A-40,926支架的修饰产生，在这些支架上的糖部分用某些酰基（特别是氨基酸和它们的衍生物）; 和/或将这些支架的大环上的酸部分转化为某些取代的酰胺; 或具有这些支架上的氨基取代的糖部分上的氨基取代基的烷基化修饰与某些烷基的组合或在该支架上的氨基取代的糖部分上的氨基取代基的某些烷基（包括β - 氨基酸或其衍生物），并将该支架的大环上的酸部分转化为某些取代的酰胺。版权所有（C）2009，JPO＆INPIT

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式